Quanterix Corporation (QTRX) Stock

Quanterix Corporation (QTRX) is a Technology stock trading at $3.12 (as of 2026-08-20), with a market capitalization of $147.55M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Quanterix develops and markets digital immunoassay platforms for life sciences research and diagnostics, including the HD-X, SR-X, and SP-X instrument systems. It also supplies assay kits and related reagents and offers services such as sample testing and custom assay development for academic and governmental labs as well as pharmaceutical and biotechnology customers.

Understand Quanterix Corporation: how it makes money

Quanterix builds digital immunoassay instruments and Simoa-based platforms (HD-X, SR-X, and SP-X), then earns money from instrument sales plus repeat usage through consumables and supporting services.

The profit engine is the installed instrument base that drives repeat consumables and ongoing platform usage, supplemented by instrument placements and services like Accelerator Lab, rather than relying on instruments alone.

Revenue by segment (latest quarter)
Consumables	$0.0B
Spatial	$0.0B
Services&Other	$0.0B
Instruments	$0.0B

Business quality (Weak): Clear platform and revenue mix (instruments, consumables, spatial, and services) with measurable operating signals like instrument placements and accelerator lab activity, but the latest quarter shows instruments and several non-core categories at 0.0 in this dataset.

Bull case

Consumables support recurring platform economics: Consumables revenue is reported separately (0.02B), which can benefit from an installed base using Quanterix detection technology.
Spatial and services add additional monetization routes: Spatial revenue is reported (0.01B), and Services and Other revenue is also reported (0.01B), supported by the company operating an Accelerator Lab (Accelerator Lab Customers, 480).

Bear case

Operating losses are severe in the latest quarter: Operating margin is -113.6% for the period ended 2026-03-31.
Instruments and other categories show 0.0 in this dataset: Instruments Revenue is 0.0B, and several additional revenue categories listed are also 0.0B, which can pressure overall results when one-time or non-consumables revenue is absent.
Near-term quarter performance may be volatile: The operating snapshot includes both instrument placement counts and accelerator activity, but the latest quarter revenue split here shows very small totals overall, which can make performance sensitive to execution timing.

Valuation — source: SEC EDGAR (first-party)
Price	$3.12
Market Cap	$147.55M
Price / Book	0.62
Price / Sales	1.01
FCF Yield	-83.6%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$138.90M
Net Margin	-77.1%
Revenue Growth (YoY)	1.1%
EPS Growth (YoY)	151.0%
FCF Growth (YoY)	107.2%

Financial Health — source: SEC EDGAR
Altman Z-Score	-1.48 (distress)

Valuation vs Sector & Industry
Sector P/E (Technology)	33.9
Industry P/E (Measuring & Control Equipment)	51.8

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	VANGUARD GROUP INC ($17.03M)
Institutional Holders Tracked	10

Company
Sector	Technology
Industry	Measuring & Control Equipment
CEO	Everett V. Cunningham
Employees	471
Country	US
IPO Date	2017-12-07

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.